{
  "USA": {
    "country": "USA",
    "original_filename": "AT201_FDA_Noncompliant_Protocol.pdf",
    "total_changes": 9,
    "chunks_processed": 14,
    "changes": [
      {
        "type": "replace",
        "original": "Adverse events will be collected voluntarily by subjects using a monthly web form.",
        "replacement": "Adverse events will be collected voluntarily by subjects using a monthly web form. Investigators will promptly review and follow up on all reported adverse events, including serious adverse events and deaths.",
        "reason": "VIOLATION 1 & 2: Ensures prompt review of all safety information and follow-up on serious adverse events from clinical investigations",
        "addresses_violation": [
          1,
          2
        ]
      },
      {
        "type": "replace",
        "original": "Investigators are not requir",
        "replacement": "Investigators are required to review all safety data from clinical investigations and promptly report serious adverse events and deaths to the sponsor.",
        "reason": "VIOLATION 1 & 2: Explicitly states investigator responsibility to review safety data and report serious events, addressing both violations",
        "addresses_violation": [
          1,
          2
        ]
      },
      {
        "type": "replace",
        "original": "No IRB or ethics committee re",
        "replacement": "IRB review and approval will be obtained prior to initiating the study. The IRB will document findings for any approved alterations to informed consent requirements.",
        "reason": "VIOLATION 1: Adds required IRB review and documentation of findings for alterations to informed consent, addressing the regulatory requirement",
        "addresses_violation": 1
      },
      {
        "type": "replace",
        "original": "Data will be retained for at least ",
        "replacement": "Data will be retained for at least 2 years after marketing application approval, or if the application is not approved, for 2 years after discontinuing investigational use.",
        "reason": "VIOLATION 1 & 2: Specifies the required 2-year retention period for both scenarios (approval and non-approval) to comply with regulations",
        "addresses_violation": 1
      },
      {
        "type": "add",
        "after": "Sites may implement their own recordkeeping systems.",
        "content": " However, all sites must adhere to the minimum data retention requirements as specified in the protocol.",
        "reason": "VIOLATION 1 & 2: Reinforces compliance with retention requirements across all sites",
        "addresses_violation": 2
      },
      {
        "type": "replace",
        "original": "The IND will be filed post-study if data appear promising.",
        "replacement": "An IND application will be submitted to the FDA before initiating the clinical investigation, containing sufficient information to assess subject risks.",
        "reason": "VIOLATIONS 1 & 2: IND must be submitted before study start with sufficient information to assess risks, not post-study",
        "addresses_violation": [
          1,
          2
        ]
      },
      {
        "type": "delete",
        "text": "No Form 1572 will be collected from investigators.",
        "reason": "VIOLATION 1: Removing statement that contradicts proper IND submission process",
        "addresses_violation": 1
      },
      {
        "type": "replace",
        "original": "Serious adverse events will be summarized in the annual report only, and not reported within the 15-day window specified in 21 CFR 312.32.",
        "replacement": "Serious unexpected adverse events with suspected drug causation will be reported within the 15-day window specified in 21 CFR 312.32, in addition to being summarized in the annual report.",
        "reason": "VIOLATION 1: Corrects the protocol to comply with the requirement to report serious unexpected adverse events within 15 days, even if they are part of the study endpoint.",
        "addresses_violation": 1
      },
      {
        "type": "replace",
        "original": "The sponsor may delegate all regulatory responsibilities to local CROs without documentation.",
        "replacement": "The sponsor may delegate some regulatory responsibilities to local CROs with proper documentation, but must retain oversight and verify physician compliance with investigator regulations.",
        "reason": "VIOLATION 1: Sponsors must maintain oversight and verify physician compliance with regulations, even when delegating tasks to CROs.",
        "addresses_violation": 1
      }
    ]
  },
  "EU": {
    "country": "EUROPE",
    "original_filename": "AT201_FDA_Noncompliant_Protocol.pdf",
    "total_changes": 0,
    "chunks_processed": 14,
    "changes": []
  },
  "JAPAN": {
    "country": "JAPAN",
    "original_filename": "AT201_FDA_Noncompliant_Protocol.pdf",
    "total_changes": 10,
    "chunks_processed": 14,
    "changes": [
      {
        "type": "replace",
        "original": "Participants will be informed verbally that their participation is optional. No written consent will be required.",
        "replacement": "Participants will be provided written information about the trial and asked to sign a written informed consent form before participation. The consent form will explain that participation is optional.",
        "reason": "VIOLATION 1 & 2: Requires written informed consent and written explanation of trial information",
        "addresses_violation": [
          1,
          2
        ]
      },
      {
        "type": "add",
        "after": "Informed Consent and Ethics Oversight",
        "content": " Written information will be provided to subjects including all required trial details as specified by regulations.",
        "reason": "VIOLATION 3: Requires providing written information with specified trial details",
        "addresses_violation": 3
      },
      {
        "type": "delete",
        "text": "No IRB or ethics committee re",
        "reason": "Incomplete sentence that may imply lack of ethics oversight. Full ethics review details should be added.",
        "addresses_violation": [
          1,
          2,
          3
        ]
      },
      {
        "type": "replace",
        "original": "No copies of consent forms will be retained.",
        "replacement": "Copies of consent forms will be retained for the required retention period.",
        "reason": "VIOLATIONS 1-4: Retaining consent forms is necessary to comply with record-keeping requirements for clinical trials",
        "addresses_violation": [
          1,
          2,
          3,
          4
        ]
      },
      {
        "type": "add",
        "after": "Copies of consent forms will be retained for the required retention period.",
        "content": " All clinical trial records will be maintained in accordance with applicable regulations.",
        "reason": "VIOLATIONS 1-4: Explicitly stating compliance with record retention requirements",
        "addresses_violation": [
          1,
          2,
          3,
          4
        ]
      },
      {
        "type": "add",
        "after": "All clinical trial records will be maintained in accordance with applicable regulations.",
        "content": " The sponsor-investigator will retain these records for the specified time periods as required by law.",
        "reason": "VIOLATION 4: Addressing the specific requirement for sponsor-investigators to retain records for specified time periods",
        "addresses_violation": 4
      },
      {
        "type": "replace",
        "original": "No Form 1572 will be collected from investigators.",
        "replacement": "Form 1572 will be collected from investigators and submitted to the head of the medical institution for approval.",
        "reason": "VIOLATION 1: Ensures required documents are submitted for approval",
        "addresses_violation": 1
      },
      {
        "type": "add",
        "after": "No invest",
        "content": "igator brochure will be provided. An investigator brochure containing written information for the clinical trial will be prepared and distributed to investigators.",
        "reason": "VIOLATION 2: Ensures written information is prepared for the clinical trial",
        "addresses_violation": 2
      },
      {
        "type": "replace",
        "original": "The IND will be filed post-study if data appear promising.",
        "replacement": "The IND, including the protocol and any amendments, will be submitted to the medical institution head prior to study initiation.",
        "reason": "VIOLATION 3: Ensures protocol is submitted to medical institution head before study starts",
        "addresses_violation": 3
      },
      {
        "type": "replace",
        "original": "The sponsor may delegate all regulatory responsibilities to local CROs without documentation.",
        "replacement": "The sponsor may delegate regulatory responsibilities to local CROs, but must maintain a contract stating the sponsor's right to verify compliance with instructions.",
        "reason": "VIOLATION 1: Ensures compliance with the requirement for a contract stating the sponsor's right to verify compliance when delegating responsibilities",
        "addresses_violation": 1
      }
    ]
  }
}